Effect of second-generation antipsychotics on cognition: current issues and future challenges. - Wikidata - wikimedia - TriplyDB

Effect of second-generation antipsychotics on cognition: current issues and future challenges.

Effect of second-generation antipsychotics on cognition: current issues and future challenges.

http://www.wikidata.org/entity/Q33888153

about

Update on the development of lurasidone as a treatment for patients with acute schizophrenia Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders.nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Differentiation of schizophrenia patients from healthy subjects by mismatch negativity and neuropsychological tests.Failures of cognitive control or attention? The case of stop-signal deficits in schizophrenia.Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Neurobiology of cognitive remediation therapy for schizophrenia: a systematic review The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia.Pharmacotherapy for treatment-resistant schizophrenia.Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study.The genetics of cognitive impairment in schizophrenia: a phenomic perspective.Sleep correlates of cognition in early course psychotic disorders.Sequential processing deficits in schizophrenia: relationship to neuropsychology and genetics.Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model Psychoactive medication use and neurocognitive function in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor study.Is psychiatry intervention in Indian setting complete?Exposure to kynurenic acid during adolescence produces memory deficits in adulthood.Low maternal hemoglobin during pregnancy and diminished neuromotor and neurocognitive performance in offspring with schizophrenia The impact of motivation on cognitive performance in an animal model of the negative and cognitive symptoms of schizophrenia.Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.ΔFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes.Generalized and specific neurocognitive deficits in psychotic disorders: utility for evaluating pharmacological treatment effects and as intermediate phenotypes for gene discovery.Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview.Pharmacogenomics can improve antipsychotic treatment in schizophrenia.Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.MK-801 Impairs Cognitive Coordination on a Rotating Arena (Carousel) and Contextual Specificity of Hippocampal Immediate-Early Gene Expression in a Rat Model of Psychosis Verbal learning and memory and their associations with brain morphology and illness course in schizophrenia spectrum psychoses.L-type Ca2+ channels in mood, cognition and addiction: integrating human and rodent studies with a focus on behavioural endophenotypes.Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review.Cognitive remediation in schizophrenia.SoCIAL - training cognition in schizophrenia: a pilot study.Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials.Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders.A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs.Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin.

P2860

Q27009585-8BE17577-219D-4935-8B33-0FA87C75A896 Q30241067-A1B25AF6-A695-4D9A-8D3B-E4C048750967 Q30362464-DC0D481D-F2DA-4502-B070-84B0308E71BF Q30468652-3871EA36-0E7A-4E7D-9A41-730D6A870FCE Q33627873-491B5C85-2ACE-486E-8BDA-40C0DF2A4884 Q33841881-47704F98-6E4A-42F0-9232-380A3415FD56 Q33936458-28455861-CB4E-4D17-9BED-F1CBA1AE20FC Q34249753-2CD370BE-D4BF-4E79-ABA4-ADAA19BC6BBD Q34274859-2C3BCF8B-3D3B-4D0D-9862-FAEE547E1068 Q34436237-69D5741C-C769-44C9-95B6-55622923E637 Q34660603-8D1AFF69-FD67-435B-9266-295B494113C8 Q34879109-70DC1DF4-F59C-4AD9-90A0-09065FC7BBFA Q35021026-2BC69283-A4CB-4E5C-94BD-68AAE8B306DD Q35186661-363D97E3-B229-4AA1-8886-D9A73D175BC2 Q35554778-BBF31613-74A3-4A0C-B1E1-8C820CC8D7C0 Q35775782-9CC2156E-2739-43A2-B9B2-37EE045B5ED3 Q35946867-7E9370FF-93F3-4902-8934-FAA9A6FF16A2 Q36219472-2C61AA09-B853-4B60-B473-17756520D5C3 Q36389088-72D39D08-B7AB-4FAC-9827-88A3E3FEC31A Q36458044-27A0912E-F228-4BB9-9A4A-8FFF568D50A3 Q36623248-D5EEF8AC-EA05-4B85-A3EF-9AFF5F1B2E36 Q36669230-38E91BED-7E92-4CA9-9086-A751764A8B0F Q36935081-F845BDD4-A830-4473-A464-4D78149C4DAC Q37331835-9584FFFA-D0F7-422F-92E9-E7F0C49B3D47 Q37491604-9F9DF39B-18E3-431D-B509-995A458B27AD Q37699383-CEF58FF7-7E03-4D30-929A-EA376654355A Q38033603-3808744D-6ACA-4345-BDB4-B34E0890C965 Q38100731-5FD167CD-E195-4E64-9076-5271B3D66D29 Q38186705-04955B06-3B3E-4EB1-A095-B04F5FACC96B Q38207021-8CACDC60-F4E6-4B54-B0C0-99F8F1E1401F Q38256077-0C94794A-4475-47D9-BCFF-8E5F92FAF26C Q38473103-FEE452D2-2208-4795-8FC0-56DE1F0557AF Q38903556-0B1C197B-A741-4E5E-8D32-7F090D36024F Q39353895-559A218A-2088-42A8-B163-7A8B1180947B Q39463534-29EBAEF8-398F-422A-A3F5-5AFB53C39EF1 Q41144296-3E81B685-166C-4F41-86CE-D001CF8D201B Q41569283-D577C445-27CC-427C-9967-C3B11EE3A4BB Q41573058-111563D8-94BF-4456-9B80-B5C0C56A2801 Q45249478-BB53F524-C3F8-47B8-9573-C902064C0F4B Q48017925-F60D5344-2AA6-4CA9-B9A5-0BDAC1AFD9E7

P2860

Effect of second-generation antipsychotics on cognition: current issues and future challenges.

http://www.wikidata.org/entity/Q33888153

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of second-generation an ...... issues and future challenges.

@ast

Effect of second-generation an ...... issues and future challenges.

@en

type

label

Effect of second-generation an ...... issues and future challenges.

@ast

Effect of second-generation an ...... issues and future challenges.

@en

prefLabel

Effect of second-generation an ...... issues and future challenges.

@ast

Effect of second-generation an ...... issues and future challenges.

@en

P1433

Q33888153-D7DECB9B-F436-4C61-BCDF-B2E559CA8109

P1476

Q33888153-55EA7A52-291D-4B9D-B95D-9EBEE336AD5D

P2093

Q33888153-73E50E98-910F-4F15-BEEF-B839F5557889

Q33888153-8BAEEF96-32F7-49A9-9FB6-0F1B6F14B2CB

Q33888153-9CFFC187-AE84-4536-89A5-DC317567EE36

Q33888153-DE0F937F-6507-41C7-9E12-AD73386E383D

P2860

Q33888153-047A8AC6-2167-407B-975C-EA7DAC95280F

Q33888153-07B13B35-14B8-46AD-8695-E6675FBA3D70

Q33888153-09AFA617-50EE-4C7C-A33D-F43ED9A056AB

Q33888153-0A30FA20-FA57-48ED-B457-C66903F8F4D1

Q33888153-0D7F6148-2FAD-4511-BDFE-2FDD2F4FC8B8

Q33888153-0FA09E94-9ADE-4B8A-AF72-AFC722228734

Q33888153-104DE058-05EE-49E7-BA73-C0EDA512459C

Q33888153-1220C00B-4D2B-4B50-803B-4604F8D6E59F

Q33888153-1328A772-5A7A-48B9-89AB-2C513AAE0B1C

Q33888153-17E65340-D5D8-47A2-A4C2-5F44065AAA29

P304

Q33888153-A8DB13E9-61FD-4D38-9815-3CA8D4AF5843

P31

Q33888153-648ED38C-B424-4516-8AB9-C865F53E5A46

P356

Q33888153-6EB894A3-1E71-4771-B0BF-FB463EE1F5A0

P433

Q33888153-F9560BF5-0B9B-4B74-9DE6-9F364A2C9A7A

P478

Q33888153-742F5CD8-25AA-4ECF-9643-53BF48227B56

P577

Q33888153-DD779EBB-A0AC-44FD-AFD9-70425D3931A1

P5875

Q33888153-0CC3CB64-C719-4883-B31B-53F5441E2345

P698

Q33888153-7A28B961-518E-491F-A60C-84EB5881EAA4

P932

Q33888153-AC949B1B-F9E8-41B8-8D31-5929ECA29BD7

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Effect of second-generation an ...... issues and future challenges.

@en

P2093

Donna Palumbo

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Bishop

http://www.w3.org/2001/XMLSchema#string

John A Sweeney

http://www.w3.org/2001/XMLSchema#string

S Kristian Hill

http://www.w3.org/2001/XMLSchema#string

P2860

GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia

Inhibition-based rhythms: experimental and mathematical observations on network dynamics

Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats

Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic

Cortical inhibitory neurons and schizophrenia

Neurophysiological biomarkers for drug development in schizophrenia.

Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies

Prefrontal neurons and the genetics of schizophrenia.

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.

P304

43-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.09.143

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40728820

http://www.w3.org/2001/XMLSchema#string

P698

20021320

http://www.w3.org/2001/XMLSchema#string

P932

2879261

http://www.w3.org/2001/XMLSchema#string